SleepMTEC Phase 2NCT07608614
Sleep and Performance
A study testing Transcranial Electric Stimulation in people with Sleep and Glymphatic System, run by University of Washington at 1 site in United States.
Trial summary
This research is being done to apply new, contrast-free MRI (Magnetic Resonance Imaging) methods to understand the brain's waste clearance system (the "glymphatic" system) in younger adults. Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Sleep, Glymphatic System
- What is being tested?
- Transcranial Electric Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2025to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Physically and psychologically healthy
- Good habitual sleep between 6 and 10 hours in duration, as assessed by questionnaire and pre-study week sleep/wake diary
- Regular bedtimes, habitually getting up between 05:00 and 09:00, as assessed by questionnaire and pre-study week sleep/wake diary
Who cannot join
- Subjects who have any type of non-MRI compatible bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.), because such devices may be displaced or malfunction.
- Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced.
- Subjects who have cerebral aneurysm
- Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers and machinists (potential for metallic fragments in or near the eyes).
- Minors (younger than 18 years)
- Pregnant women ( Participants of childbearing potential will receive a urine pregnancy test. If the test is positive, the participant will be excluded)
Show all 23Show fewer
- Breastfeeding
- Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher.
- no clinical disorders and/or illnesses, no psychiatric illnesses), as assessed by history and questionnaires
- no alcohol during study and no normal excessive alcohol consumption assessed by questionnaire
- No history of drug or alcohol abuse in the past year and no history of methamphetamine abuse, as assessed by questionnaires.
- Not a dependent smoker or vaper, and not morning dependent on tobacco, nicotine, or cannabis, as assessed by questionnaire.
- No history of moderate to severe brain injury, as assessed by questionnaire
- No anti-psychotic medication for ADHD/ADD, as assessed by questionnaire
- No previous adverse reaction to sleep deprivation, as assessed by questionnaire
- Not vision-impaired unless corrected back to normal.
- Not hearing impaired unless corrected to normal, as assessed by questionnaire
- Not pregnant, as assessed by history and questionnaire
- No sleep or circadian disorder, as assessed by questionnaires
- No use of melatonin within 1 week of study enrollment
- No travel across more than one time zone within one month of entering the study and no crossing times zones during study participation, as assessed by questionnaire.
- No shift work within three months of entering the study and no shift work during duration study participation, as assessed by questionnaire.
- epilepsy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Maria Tsimpanouli contact
United States1 site, 1 recruiting
- Recruiting
University of Washington School of Medicine
Seattle, Washington, 98125
Yeilim Cho, MD, (206) 277-7207, ycho7@uw.edu
About this study
Official title: Augmented Neurophysiology of Sleep and Performance Readiness
This research is being done to apply new, contrast-free MRI (Magnetic Resonance Imaging) methods to understand the brain's waste clearance system (the "glymphatic" system) in younger adults. The Investigators hope the study will show how the different brain regions are involved in maintaining memories and how poor sleep affects these regions and our ability to remember. The Investigators will test whether the Wireless Interface Sensor Pod (WISP) improves brain function after poor sleep. The WISP is a headband that combines tracking brain waves and transcranial electrical stimulation (TES) to monitor and improve slow wave sleep and glymphatic clearance.
IParticipants will be asked to:
- Complete 4 in-person study visits (1 per week) over 4 weeks at the Diagnostic Imaging Sciences Center (DISC), located at the University of Washington Medical Center at Montlake, Seattle. Each visit will last 2 hours and includes a 1 hour MRI and 1 hour of cognitive testing.
- Complete a daily journal about sleep, daily habits, etc.
- The night before each of the four study visits, participants will sleep while wearing the WISP headband.
- For two of these nights, participants will sleep only 3 hours prior to normal time of awakening. The WISP will deliver a small electrical current for one night and not for the other night, but participants will not know which.
- For the other two nights, participants will follow a normal sleep schedule. The WISP will deliver a small electrical current for one night and not for the other night, but participants will not know which.
Read the detailed description
Sleep is a fundamental element of brain health and function, supporting the processes of learning and memory consolidation, maintenance and repair, and waste clearance. Acute sleep deprivation, a frequent operational necessity among warfighters, significantly impairs attention, vigilance, processing speed, executive function, motor coordination and memory. Chronic sleep restriction, a condition common among service members during combat deployments and operations, erodes cognitive and physical performance and is a major limitation on sustained operational readiness.
The newly-discovered glymphatic system supports the rapid exchange of fluid through brain tissue during sleep, facilitating the clearance of wastes that accumulate through the course of waking activity. Increased glymphatic clearance occurs in the deepest (slow wave, N3) stage of sleep and is facilitated by the dynamic enlargement of the brain's extracellular space during slow wave activity. Sleep-active glymphatic function is postulated to underlie the restorative function of sleep on cognition, and its impairment is proposed to drive the cognitive impacts of sleep disruption. This suggests that improving glymphatic function, whether pharmacologically or by means of a device, could ameliorate the cognitive effects of acute sleep deprivation and chronic sleep restriction.
The proposed technology, Augmented Neural Oscillation Driver or 'AugNOD', is an easily-applied, wireless, combined electroencephalography (EEG)/transcranial electrical stimulation (TES) headband that can be applied before sleep to monitor and improve slow wave sleep and glymphatic clearance. The AugNOD system utilizes two complimentary protocols to support glymphatic function: 1) the integrated TES Slow Oscillation (TES SO) promotes slow wave sleep, engaging sleep-active glymphatic clearance; 2) the Direct Current Glymphatic Clearance (DCGC) protocol directly improves glymphatic function through enhancement of brain extracellular diffusion. BEL has obtained an FDA presubmission query for the Neurosom EEG Assessment Technology (NEAT) for automated sleep staging using machine learning (Convolutional Neural Nets) with validation from AASM-Certified commercial scoring. This should complete soon, and the Investigators expect FDA clearance for NEAT by early 2022. In addition, BEL has obtained an FDA review for TES synchronization of SOs with the Intended Use of improving deep sleep (N3) in healthy adults.
Although the presence of sleep-active glymphatic exchange has only recently been confirmed in human subjects, no pharmacological or device-based approach has yet demonstrated that glymphatic function can be modulated in the human brain. In Objective 1, the investigators will test whether enhancing slow wave sleep using the AugNOD TES SO protocol improves overnight glymphatic function measured by MRI. By comparing effects between subject undergoing total sleep deprivation, restricted natural sleep, and restricted natural sleep with TES slow wave synchronization, this study will determine whether extending slow wave sleep with TES leads to improvement of glymphatic clearance and regional molecular diffusion by multimodal MRI, The Investigators will also perform Magnetic Resonance Elastography (MRE) on the healthy human brain in multiple directions to calculate directional stiffness of the brain tissue. An MRE actuator vibrational device (pillow) will be used to apply vibration to the subject's head in one direction and then another, and then to use this information to calculate the stiffness of brain tissue. The investigators will combine the information from the MRE scan and the information from the other MRI scans performed to simulate brain motion and calculate accurate mechanical properties of the brain.
Although glymphatic function has been proposed to underlie the restorative effects of sleep on cognitive function, and its impairment has been thought to contribute to cognitive deficits resulting from sleep deprivation, this connection has never been directly tested experimentally in animal models or in human subjects. In Objective 2, the research will test whether AugNOD TES SO improves sleep restriction-associated cognitive impairment. Sleep restriction will be coupled with a demanding vigilance task to simulate the challenges of performance under operational conditions. Since slow wave sleep likely exerts a restorative effect on cognitive function independent of glymphatic clearance, the TES SO protocol may also improve subsequent cognitive performance through enhancement of sleep efficiency.
- Conditions
- Sleep, Glymphatic System
- Being tested
- Transcranial Electric Stimulation, Sham Comparator
- Keywords
- sleep, glymphatic system, cognitive function
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transcranial Electric StimulationDevice
Participants will wear the Wireless Interface Sensor Pod (WISP), which combines EEG with Transcranial Electrical Stimulation (TES)
Sham ComparatorDevice
Participants will wear the WISP device, but no TES
| Study group | Role | What they receive |
|---|---|---|
| Sleep restriction, no TES | Sham comparator | Participants will have sleep restriction, sham TES Receives: Device: Sham Comparator |
| Sleep restriction, TES | Experimental | Participants will have sleep restriction, will have active TES Receives: Device: Transcranial Electric Stimulation |
| Normal sleep, no TES | Sham comparator | Participants will follow normal sleep schedule, sham TES Receives: Device: Sham Comparator |
| Normal sleep, TES | Experimental | Participants will follow normal sleep schedule, will have TES Receives: Device: Transcranial Electric Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Multimodal MRI
We will test whether enhancing slow-wave sleep using the AugNOD TES SO improves overnight glymphatic function, as measured by non-invasive multimodal MRI-based markers of glymphatic activity: (i) diffusion-based intravoxel incoherent motion (IVIM)-MRI assessing long-distance water transport (diffusion signal); (ii) fast functional MRI (f-MRI) measuring low-frequency vasomotor oscillations; (iii) T1/FLAIR-based assessment of MRI-visible perivascular spaces (MV-PVS), which serve as structural indicators of perivascular impairment; (iv) multi-echo arterial spin-labeling (ME-ASL)-MRI assessing glial-vascular water transport ; and (v) Magnetic Resonance Elastography (MRE) measuring brain tissue stiffness.
Measured: Immediately after the intervention with sleep condition and TES
Secondary outcomes (5)
Psychomotor Vigilance Task (PVT)
The PVT is a test of sustained attention, measuring the speed at which individuals respond to visual stimuli. The test requires participants to rapidly respond to visual cues presented within specified interstimulus intervals. Participants are asked to press a button as soon as they see a light appear on a screen, with the light turning on at random intervals, Response times are recorded and evaluated.
Measured: Immediately after the intervention with sleep condition and TES
Go/no go task
A decision-making task that requires a participant to respond or withhold a response based on feedback from the computer using arrows or numbers as cues. Number of errors are recorded.
Measured: Immediately after the intervention with sleep condition and TES
The Digit Symbol Substitution Test (DSST)
A brief timed coding task (typically 90-120 seconds) in which people use a key to pair digits with symbols and produce as many correct matches as possible. Number of errors will be recorded
Measured: Immediately after the intervention with sleep condition and TES
Digit Span
Participants are asked to recall sequences of numbers in order. The longest sequence will be measured.
Measured: Immediately after the intervention with sleep condition and TES
Positive and Negative Affect Schedule (PANAS)
20-item self- report measure to assess positive affect (PA) and negative affect (NA) on a 5-point Likert scale. Total positive and total negative affect scores will be recorded.
Measured: Immediately after the intervention with sleep condition and TES
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2026
- Study start1 Oct 2025
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SleepStudies of the same condition, open and under way.
- More trials run by University of WashingtonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Collaborators
- Medical Technology Enterprise Consortium
- Responsible party
- Principal investigator, Jeffrey John Iliff, University of Washington
- Investigators
- Jeffrey Iliff, PhD, Principal investigator, University of Washington
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07608614
- Sponsor's protocol ID
- STUDY00021849
- Other IDs
- W81XWH-21-09-0021-129
- Acronym
- MTEC Phase 2
- Status last verified
- May 2026
- First submitted
- 12 May 2026
- Last updated
- 27 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Augmented Neurophysiology of Sleep and Performance Readiness
- ClinicalTrials.gov ID
- NCT07608614
- Acronym / sponsor ID
- MTEC Phase 2 / STUDY00021849
- Conditions
- Sleep, Glymphatic System
- Keywords
- sleep, glymphatic system, cognitive function
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- University of WashingtonUniversity, hospital or other
- Collaborators
- Medical Technology Enterprise Consortium
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 27 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research is being done to apply new, contrast-free MRI (Magnetic Resonance Imaging) methods to understand the brain's waste clearance system (the "glymphatic" system) in younger adults. The Investigators hope the study will show how the different brain regions are involved in maintaining memories and how poor sleep affects these regions and our ability to remember. The Investigators will test whether the Wireless Interface Sensor Pod (WISP) improves brain function after poor sleep. The WISP is a headband that combines tracking brain waves and transcranial electrical stimulation (TES) to monitor and improve slow wave sleep and glymphatic clearance.
IParticipants will be asked to:
- Complete 4 in-person study visits (1 per week) over 4 weeks at the Diagnostic Imaging Sciences Center (DISC), located at the University of Washington Medical Center at Montlake, Seattle. Each visit will last 2 hours and includes a 1 hour MRI and 1 hour of cognitive testing.
- Complete a daily journal about sleep, daily habits, etc.
- The night before each of the four study visits, participants will sleep while wearing the WISP headband.
- For two of these nights, participants will sleep only 3 hours prior to normal time of awakening. The WISP will deliver a small electrical current for one night and not for the other night, but participants will not know which.
- For the other two nights, participants will follow a normal sleep schedule. The WISP will deliver a small electrical current for one night and not for the other night, but participants will not know which.
Detailed description
Sleep is a fundamental element of brain health and function, supporting the processes of learning and memory consolidation, maintenance and repair, and waste clearance. Acute sleep deprivation, a frequent operational necessity among warfighters, significantly impairs attention, vigilance, processing speed, executive function, motor coordination and memory. Chronic sleep restriction, a condition common among service members during combat deployments and operations, erodes cognitive and physical performance and is a major limitation on sustained operational readiness.
The newly-discovered glymphatic system supports the rapid exchange of fluid through brain tissue during sleep, facilitating the clearance of wastes that accumulate through the course of waking activity. Increased glymphatic clearance occurs in the deepest (slow wave, N3) stage of sleep and is facilitated by the dynamic enlargement of the brain's extracellular space during slow wave activity. Sleep-active glymphatic function is postulated to underlie the restorative function of sleep on cognition, and its impairment is proposed to drive the cognitive impacts of sleep disruption. This suggests that improving glymphatic function, whether pharmacologically or by means of a device, could ameliorate the cognitive effects of acute sleep deprivation and chronic sleep restriction.
The proposed technology, Augmented Neural Oscillation Driver or 'AugNOD', is an easily-applied, wireless, combined electroencephalography (EEG)/transcranial electrical stimulation (TES) headband that can be applied before sleep to monitor and improve slow wave sleep and glymphatic clearance. The AugNOD system utilizes two complimentary protocols to support glymphatic function: 1) the integrated TES Slow Oscillation (TES SO) promotes slow wave sleep, engaging sleep-active glymphatic clearance; 2) the Direct Current Glymphatic Clearance (DCGC) protocol directly improves glymphatic function through enhancement of brain extracellular diffusion. BEL has obtained an FDA presubmission query for the Neurosom EEG Assessment Technology (NEAT) for automated sleep staging using machine learning (Convolutional Neural Nets) with validation from AASM-Certified commercial scoring. This should complete soon, and the Investigators expect FDA clearance for NEAT by early 2022. In addition, BEL has obtained an FDA review for TES synchronization of SOs with the Intended Use of improving deep sleep (N3) in healthy adults.
Although the presence of sleep-active glymphatic exchange has only recently been confirmed in human subjects, no pharmacological or device-based approach has yet demonstrated that glymphatic function can be modulated in the human brain. In Objective 1, the investigators will test whether enhancing slow wave sleep using the AugNOD TES SO protocol improves overnight glymphatic function measured by MRI. By comparing effects between subject undergoing total sleep deprivation, restricted natural sleep, and restricted natural sleep with TES slow wave synchronization, this study will determine whether extending slow wave sleep with TES leads to improvement of glymphatic clearance and regional molecular diffusion by multimodal MRI, The Investigators will also perform Magnetic Resonance Elastography (MRE) on the healthy human brain in multiple directions to calculate directional stiffness of the brain tissue. An MRE actuator vibrational device (pillow) will be used to apply vibration to the subject's head in one direction and then another, and then to use this information to calculate the stiffness of brain tissue. The investigators will combine the information from the MRE scan and the information from the other MRI scans performed to simulate brain motion and calculate accurate mechanical properties of the brain.
Although glymphatic function has been proposed to underlie the restorative effects of sleep on cognitive function, and its impairment has been thought to contribute to cognitive deficits resulting from sleep deprivation, this connection has never been directly tested experimentally in animal models or in human subjects. In Objective 2, the research will test whether AugNOD TES SO improves sleep restriction-associated cognitive impairment. Sleep restriction will be coupled with a demanding vigilance task to simulate the challenges of performance under operational conditions. Since slow wave sleep likely exerts a restorative effect on cognitive function independent of glymphatic clearance, the TES SO protocol may also improve subsequent cognitive performance through enhancement of sleep efficiency.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Sleep restriction, no TES | Sham comparator | Device: Sham ComparatorParticipants will have sleep restriction, sham TES |
| Sleep restriction, TES | Experimental | Device: Transcranial Electric StimulationParticipants will have sleep restriction, will have active TES |
| Normal sleep, no TES | Sham comparator | Device: Sham ComparatorParticipants will follow normal sleep schedule, sham TES |
| Normal sleep, TES | Experimental | Device: Transcranial Electric StimulationParticipants will follow normal sleep schedule, will have TES |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Physically and psychologically healthy
- Good habitual sleep between 6 and 10 hours in duration, as assessed by questionnaire and pre-study week sleep/wake diary
- Regular bedtimes, habitually getting up between 05:00 and 09:00, as assessed by questionnaire and pre-study week sleep/wake diary
Key exclusion criteria (23 listed)
- Subjects who have any type of non-MRI compatible bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, etc.), because such devices may be displaced or malfunction.
- Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced.
- Subjects who have cerebral aneurysm
- Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers and machinists (potential for metallic fragments in or near the eyes).
- Minors (younger than 18 years)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transcranial Electric StimulationParticipants will wear the Wireless Interface Sensor Pod (WISP), which combines EEG with Transcranial Electrical Stimulation (TES) | Device | Normal sleep, TES, Sleep restriction, TES |
| Sham ComparatorParticipants will wear the WISP device, but no TES | Device | Normal sleep, no TES, Sleep restriction, no TES |
Primary outcome
Multimodal MRI
Time frame: Immediately after the intervention with sleep condition and TES
We will test whether enhancing slow-wave sleep using the AugNOD TES SO improves overnight glymphatic function, as measured by non-invasive multimodal MRI-based markers of glymphatic activity: (i) diffusion-based intravoxel incoherent motion (IVIM)-MRI assessing long-distance water transport (diffusion signal); (ii) fast functional MRI (f-MRI) measuring low-frequency vasomotor oscillations; (iii) T1/FLAIR-based assessment of MRI-visible perivascular spaces (MV-PVS), which serve as structural indicators of perivascular impairment; (iv) multi-echo arterial spin-labeling (ME-ASL)-MRI assessing glial-vascular water transport ; and (v) Magnetic Resonance Elastography (MRE) measuring brain tissue stiffness.
5 secondary outcomes
Psychomotor Vigilance Task (PVT)
Time frame: Immediately after the intervention with sleep condition and TES
Go/no go task
Time frame: Immediately after the intervention with sleep condition and TES
The Digit Symbol Substitution Test (DSST)
Time frame: Immediately after the intervention with sleep condition and TES
Digit Span
Time frame: Immediately after the intervention with sleep condition and TES
Positive and Negative Affect Schedule (PANAS)
Time frame: Immediately after the intervention with sleep condition and TES
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
Related trials for Sleep
Recruiting
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue
Recruiting
The Sleep2BWell Trial
Blood Pressure, Sleep Health
Recruiting
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
Obstructive Sleep Apnea, Cognitive Decline
Not yet recruitingObservational study
Stress, Coping, and Sleep Health Study
Sleep
Recruiting
Smith Magenis Syndrome and Autism Spectrum Disorders
Smith-Magenis Syndrome, Autism Spectrum Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maria Tsimpanouli contact
Jeffrey Iliff, PhD principal investigator
University of Washington
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transcranial Electric Stimulation in people with Sleep and Glymphatic System, run by University of Washington at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yeilim Cho, MD ((206) 277-7207, ycho7@uw.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Multimodal MRI (time frame: Immediately after the intervention with sleep condition and TES). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.